The Side Effects of Gileads TDF Drugs

 

The side effects of Gileads TDF Drugs are extremely concerning. As a matter of fact, nearly 20,000 people have developed kidney damage or other complications after taking the drug. Kidney damage is especially dangerous because the kidneys are remarkably resilient, and the damage they do can be irreversible. Acute kidney failure and acute kidney injury are two of the most common complications caused by these drugs.

A class action lawsuit aimed at recovering damages from Gileads TDF drugs has been filed by thousands of individuals. The lawsuits allege that the company withheld a safer alternative to TDF. The companies' failure to provide a safe alternative may increase the payout from TDF lawsuits. Further, Gilead has threatened to pay punitive damages if its products are found to be dangerous.

As the most common side effect of TDF drugs, kidney damage and bone loss are the most common. Gilead allegedly knew about the risks of these drugs, but delayed their release until the side effects could be eliminated. This delay allowed Gilead to protect their profits by delaying the introduction of less toxic HIV medications. Executives of the company knew about the risks of tenofovir for years, but chose to conceal them, instead of releasing safer alternatives.

The company is also facing a class action lawsuit for the side effects associated with Truvada. Plaintiffs allege that Gilead failed to warn doctors and patients about the dangers associated with Truvada, a new drug for AIDS. Furthermore, the company is accused of suppressing the research of safer alternatives in order to maximize profits. To date, hundreds of these lawsuits are pending in federal and state courts across the country, and at least one class action has been filed in California.

TDF drugs were first approved for HIV infection in adults in 2001 and were expanded to chronic hepatitis B in 2008 and in children in 2012. In 2011, Gilead also introduced new combination products containing TDF, including Viread. Moreover, Truvada is now used as pre-exposure prophylaxis, or PrEP, to protect people from HIV infection. In short, the drugs slow down the progression of HIV and can keep HIV-positive patients healthy for many years. Not taking Gilead’s TDF Drugs is not a viable option for those suffering from HIV.

While Gileads TDF drugs have been highly successful in the market, their patents expired in 2016 and 2017. As a result, the company is reevaluating their drug development strategy and determining whether or not they should invest in TDF products. In addition to this, Gilead is also looking at TAF drugs in Brazil and India to address the shortage of TDF. Further, the company is evaluating other options for its future.

The lawsuit against Gileads TDF Drugs alleges that the company failed to warn about serious adverse health effects of TDF drugs, and intentionally delayed the release of a safer alternative drug. The lawsuit alleges that Gilead has systematically misled patients and deprived them of the treatment that could have saved their lives. This case has been filed in a number of state courts throughout the U.S.